| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1940-6207.CAPR-08-0042 |
| P8608 | Fatcat ID | release_crja4km2fffpbkcdwkzemgegou |
| P932 | PMC publication ID | 2562024 |
| P698 | PubMed publication ID | 18841250 |
| P50 | author | Frank L. Meyskens, Jr. | Q22006852 |
| P2093 | author name string | Michael J Lawson | |
| Daniel L Gillen | |||
| Dennis J Ahnen | |||
| Ernest Hawk | |||
| Christine E McLaren | |||
| Eugene W Gerner | |||
| Curt H Hagedorn | |||
| Philip M Carpenter | |||
| D Kim Turgeon | |||
| Peter Lance | |||
| John McCracken | |||
| C Gregory Albers | |||
| Daniel Pelot | |||
| Gary Kelloff | |||
| Jayashri Kidao | |||
| Sharon Fujikawa-Brooks | |||
| Steven Goldschmid | |||
| P2860 | cites work | A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer | Q28195274 |
| A randomized trial of aspirin to prevent colorectal adenomas | Q28195296 | ||
| Celecoxib for the prevention of sporadic colorectal adenomas | Q28200368 | ||
| Celecoxib for the prevention of colorectal adenomatous polyps | Q28200375 | ||
| A Multiple Testing Procedure for Clinical Trials | Q28248823 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention | Q29620087 | ||
| Deaths: final data for 2004. | Q31128595 | ||
| Development of difluoromethylornithine (DFMO) as a chemoprevention agent. | Q33650043 | ||
| Comparative toxicity of nonsteroidal anti-inflammatory drugs | Q33813195 | ||
| Risk of cardiovascular events associated with selective COX-2 inhibitors | Q34087109 | ||
| Polyamines and cancer: old molecules, new understanding | Q34362757 | ||
| Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group | Q34487340 | ||
| Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. | Q34508312 | ||
| A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. | Q34572357 | ||
| Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup | Q34728738 | ||
| Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis | Q34729756 | ||
| Lifestyle and medical approaches to cancer prevention. | Q36008153 | ||
| Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention | Q36775315 | ||
| Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? | Q40463586 | ||
| Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology | Q40831723 | ||
| Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention | Q44788424 | ||
| Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps | Q46301309 | ||
| The dilemma and promise of cancer chemoprevention. | Q50922961 | ||
| Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil | Q70316865 | ||
| Combination chemoprevention of cancer | Q71373151 | ||
| Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine | Q73245218 | ||
| A unifying family of group sequential test designs | Q73789846 | ||
| Combinatorial chemoprevention of intestinal neoplasia | Q74268548 | ||
| Flexible implementations of group sequential stopping rules using constrained boundaries | Q76350392 | ||
| Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer | Q79442096 | ||
| P433 | issue | 1 | |
| P921 | main subject | placebo | Q269829 |
| prevention | Q1717246 | ||
| P304 | page(s) | 32-38 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Cancer Prevention Research | Q2665103 |
| P1476 | title | Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial | |
| P478 | volume | 1 |
| Q35644191 | A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma |
| Q37285560 | A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice |
| Q36457059 | A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity |
| Q33584310 | A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer |
| Q35388587 | A simple and sensitive assay for eflornithine quantification in rat brain using pre-column derivatization and UPLC-MS/MS detection |
| Q33517982 | A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. |
| Q39185908 | AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport |
| Q48506495 | Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases |
| Q51662524 | An intermittent approach for cancer chemoprevention. |
| Q38384888 | An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis |
| Q33720933 | Apigenin Inhibits Human SW620 Cell Growth by Targeting Polyamine Catabolism. |
| Q35673251 | Arginine and polyamines in Helicobacter pylori-induced immune dysregulation and gastric carcinogenesis |
| Q37682140 | Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. |
| Q38730064 | Aspirin and colorectal cancer: the promise of precision chemoprevention. |
| Q34992425 | Aspirin and familial adenomatous polyposis: coming full circle |
| Q38036541 | Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms |
| Q46124744 | Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. |
| Q22306433 | Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview |
| Q57316214 | Aspirin, salicylates and cancer: report of a meeting at the Royal Society of Medicine, London, 23 November 2010 |
| Q36359593 | Assessing toxicity in cancer chemoprevention trials: the other side of the coin |
| Q37233040 | Associations between urinary soy isoflavonoids and two inflammatory markers in adults in the United States in 2005-2008. |
| Q37403674 | Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival |
| Q27023485 | At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer |
| Q33911623 | At the bedside: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. |
| Q34581082 | BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs. |
| Q36616621 | Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach |
| Q38879552 | Bioengineered Colorectal Cancer Drugs: Orally Delivered Anti-Inflammatory Agents |
| Q26774585 | Biomarkers in phase I-II chemoprevention trials: lessons from the NCI experience |
| Q98177417 | Calcium Permeable Channels in Cancer Hallmarks |
| Q36018371 | Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials |
| Q38652183 | Cancer Prevention: Lessons Learned and Future Directions |
| Q37002946 | Cancer Prevention: Obstacles, Challenges and the Road Ahead. |
| Q34139732 | Cancer and inflammation: promise for biologic therapy. |
| Q53235234 | Cancer chemoprevention is not a failure. |
| Q37681944 | Cancer chemoprevention locks onto a new polyamine metabolic target |
| Q37003415 | Cancer chemoprevention: a rapidly evolving field. |
| Q26852358 | Cancer chemoprevention: successes and failures |
| Q57792067 | Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer |
| Q33726196 | Cancer prevention research - then and now |
| Q34604351 | Chemo/Dietary prevention of cancer: perspectives in China |
| Q57035007 | Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials |
| Q34359198 | Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis |
| Q27023845 | Chemoprevention in familial adenomatous polyposis |
| Q34170508 | Chemoprevention in patients with genetic risk of colorectal cancers |
| Q90346571 | Chemoprevention of Colorectal Cancer |
| Q28589784 | Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis |
| Q36715105 | Chemoprevention of gastrointestinal cancer: the reality and the dream |
| Q38812583 | Chemoprevention of hereditary colon cancers: time for new strategies |
| Q33642396 | Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032 |
| Q38002127 | Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. |
| Q27026428 | Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer |
| Q35624238 | Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds |
| Q34296467 | Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer |
| Q49600966 | Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas |
| Q34772169 | Clinical trials update: Tertiary prevention of colorectal cancer |
| Q58795088 | Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives |
| Q37092129 | Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. |
| Q54172424 | Colon cancer: preventive agents and the present status of chemoprevention |
| Q37795256 | Colorectal Cancer: What Should Patients and Families Be Told to Lower the Risk of Colorectal Cancer? |
| Q34858067 | Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions |
| Q41979457 | Colorectal adenoma recurrence rates among post-polypectomy patients in the placebo-controlled groups of randomized clinical trials: a meta-analysis |
| Q24620457 | Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? |
| Q30726318 | Colorectal cancer predicted risk online (CRC-PRO) calculator using data from the multi-ethnic cohort study |
| Q49391998 | Colorectal cancer prevention: Immune modulation taking the stage |
| Q37152797 | Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation |
| Q45329573 | Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis |
| Q33895607 | Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo |
| Q28481378 | Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage |
| Q34342744 | Combined benefit of prediction and treatment: a criterion for evaluating clinical prediction models |
| Q46412218 | Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance |
| Q37785218 | Conducting Chemoprevention Clinical Trials: Challenges and Solutions |
| Q38409303 | Consumption of Red/Processed Meat and Colorectal Carcinoma: Possible Mechanisms Underlying the Significant Association |
| Q35529238 | Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention |
| Q34542215 | Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant |
| Q58715258 | Curcumin mediates polyamine metabolism and sensitizes gastrointestinal cancer cells to antitumor polyamine-targeted therapies |
| Q34065803 | Current concepts in colorectal cancer prevention |
| Q34195623 | Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention |
| Q35583635 | DFMO: targeted risk reduction therapy for colorectal neoplasia |
| Q35064943 | Defining the role of polyamines in colon carcinogenesis using mouse models |
| Q37679982 | Design of polyamine-based therapeutic agents: new targets and new directions |
| Q33519596 | Determination of eflornithine enantiomers in plasma by precolumn derivatization with o-phthalaldehyde-N-acetyl-L-cysteine and liquid chromatography with UV detection. |
| Q35891459 | Dietary polyamine intake and colorectal cancer risk in postmenopausal women |
| Q50460669 | Dietary polyamine intake and polyamines measured in urine. |
| Q36030441 | Dietary polyamine intake and risk of colorectal adenomatous polyps |
| Q35409119 | Differential control of growth, apoptotic activity and gene expression in human colon cancer cells by extracts derived from medicinal herbs, Rhazya stricta and Zingiber officinale and their combination |
| Q50084342 | Differential preventive activity of sulindac and atorvastatin in Apc(+/Min-FCCC)mice with or without colorectal adenomas |
| Q34518736 | Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells |
| Q38765477 | Difluoromethylornithine in cancer: new advances |
| Q28477296 | Difluoromethylornithine is a novel inhibitor of Helicobacter pylori growth, CagA translocation, and interleukin-8 induction |
| Q33859016 | Difluoromethylornithine: the proof is in the polyamines |
| Q33883491 | Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase |
| Q37605450 | Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma |
| Q47367989 | Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? |
| Q37785214 | Drug Development for Cancer Chemoprevention: Focus on Molecular Targets |
| Q64272815 | Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
| Q29619860 | Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) |
| Q45720383 | Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. |
| Q33739788 | Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials |
| Q52720148 | Effects of talactoferrin alpha on lung adenoma prevention in A/J mice June 2, 2016. |
| Q35027354 | Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling |
| Q31094373 | Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial |
| Q34251168 | Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53 |
| Q34734130 | Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J mice |
| Q33655389 | Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail |
| Q92015590 | Evaluation of the STAT3 inhibitor GLG‑302 for the prevention of estrogen receptor‑positive and ‑negative mammary cancers |
| Q35386279 | Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer |
| Q37785213 | Further Thoughts on Preclinical Animal Models for Cancer Prevention: When Is It Best to Start Treatment? What Are Potential Histopathologic Endpoints? |
| Q38059780 | Future directions in cancer prevention |
| Q39844175 | Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. |
| Q90748460 | Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine |
| Q30362087 | Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity. |
| Q34142332 | Identification of unique expression signatures and therapeutic targets in esophageal squamous cell carcinoma |
| Q35133419 | Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase. |
| Q33949553 | Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity |
| Q35048829 | Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis |
| Q61818514 | Inhibition of Polyamine Biosynthesis Reverses Ca Channel Remodeling in Colon Cancer Cells |
| Q37318415 | Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma |
| Q34094986 | Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination |
| Q90683901 | Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models |
| Q42574095 | Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer |
| Q35046326 | Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. |
| Q48021881 | Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model |
| Q34551546 | Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis |
| Q34716848 | Intranasal delivery of liposomal indole-3-carbinol improves its pulmonary bioavailability |
| Q38878301 | Is There a Future for Chemoprevention of Prostate Cancer? |
| Q36638469 | Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo |
| Q36102886 | Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma |
| Q37271598 | Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor |
| Q43105749 | Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas |
| Q37365983 | Mammalian polyamine metabolism and function |
| Q34097339 | Meat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California Teachers Study |
| Q36450416 | Meat consumption, ornithine decarboxylase gene polymorphism, and outcomes after colorectal cancer diagnosis |
| Q55081704 | Metformin Induces Apoptosis and Alters Cellular Responses to Oxidative Stress in Ht29 Colon Cancer Cells: Preliminary Findings. |
| Q42920181 | Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial |
| Q35963205 | Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial |
| Q38204181 | Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development |
| Q34618239 | Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents |
| Q37809351 | Molecular Targets and Clinical Cancer Risk Reductive Interventions |
| Q26797207 | Molecular cancer prevention: Current status and future directions |
| Q38696314 | Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1. |
| Q37402403 | Molecular targets for cancer chemoprevention |
| Q34205937 | Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis |
| Q37090445 | Mouse models for the study of colon carcinogenesis |
| Q34342182 | Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis |
| Q36381490 | NSAIDs and Colorectal Cancer Control: Promise and Challenges |
| Q38169133 | NSAIDs inhibit tumorigenesis, but how? |
| Q52742485 | Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers. |
| Q27653732 | New Insights into the Design of Inhibitors of Human S -Adenosylmethionine Decarboxylase: Studies of Adenine C 8 Substitution in Structural Analogues of S -Adenosylmethionine † |
| Q37191199 | Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis |
| Q27021094 | Notes from the field: "green" chemoprevention as frugal medicine |
| Q35562940 | Nrf2-dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde. |
| Q46068361 | Off-label use of approved drugs |
| Q35778754 | Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes |
| Q88938416 | Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses |
| Q34176387 | Ornithine Decarboxylase-1 Polymorphism, Chemoprevention With Eflornithine and Sulindac, and Outcomes Among Colorectal Adenoma Patients |
| Q46636207 | Ornithine decarboxylase as a therapeutic target for endometrial cancer |
| Q35064951 | Perspective: Chemoprevention of colorectal neoplasia: Translating scientific promise into clinical practice |
| Q83692752 | Perspective: The big C - for Chemoprevention |
| Q37719555 | Pharmacotherapy for inherited colorectal cancer |
| Q34112511 | Phase II cancer prevention clinical trials |
| Q36653477 | Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm |
| Q35091403 | Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice |
| Q34172667 | Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice |
| Q34253357 | Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect |
| Q58772433 | Polyamine Biosynthetic Pathway as a Drug Target for Osteosarcoma Therapy |
| Q62555115 | Polyamine metabolism and cancer: treatments, challenges and opportunities |
| Q41107342 | Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. |
| Q58596589 | Polyamine synthesis as a target of MYC oncogenes |
| Q34258829 | Polyamines Impair Immunity to Helicobacter pylori by Inhibiting L-Arginine Uptake Required for Nitric Oxide Production |
| Q26864516 | Polyamines and cancer: implications for chemotherapy and chemoprevention |
| Q38315056 | Polyamines are oncometabolites that regulate the LIN28/let-7 pathway in colorectal cancer cells |
| Q37679988 | Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention |
| Q38257840 | Polyamines metabolism and breast cancer: state of the art and perspectives |
| Q37411908 | Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer |
| Q35996689 | Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents |
| Q64433311 | Prevention of Colorectal Neoplasia |
| Q35251869 | Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy |
| Q36745841 | Prevention trials: their place in how we understand the value of prevention strategies |
| Q53509134 | Prevention: Tending the gut. |
| Q34447238 | Primary prevention of colorectal cancer: myth or reality? |
| Q35054256 | Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival |
| Q35722470 | Progress against cancer (1971-2011): how far have we come? |
| Q50111084 | Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy |
| Q35095334 | RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers |
| Q34615197 | Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention |
| Q37603293 | Rapidly cycling Lgr5+ stem cells are exquisitely sensitive to extrinsic dietary factors that modulate colon cancer risk |
| Q37522449 | Recent advances in the development of polyamine analogues as antitumor agents |
| Q62801972 | Reduction in polyamine catabolism leads to spermine-mediated airway epithelial injury and induces asthma features |
| Q39656332 | Reduction of the putative CD44+CD24− breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047 |
| Q47181119 | Regulation of Polyamine Metabolism by Curcumin for Cancer Prevention and Therapy |
| Q35562888 | Regulation of VDR Expression in Apc-Mutant Mice, Human Colon Cancers and Adenomas |
| Q30498812 | Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic |
| Q92259805 | Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy |
| Q88147711 | Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas |
| Q34605058 | Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas |
| Q37331465 | Role of apoptosis in colon cancer biology, therapy, and prevention |
| Q36671933 | Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas |
| Q36236838 | Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas |
| Q36401976 | S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion. |
| Q42085336 | Say what? The activity of the polyamine biosynthesis inhibitor difluoromethylornithine in chemoprevention is a result of reduced thymidine pools? |
| Q90473938 | Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression |
| Q91635275 | Searching for Drug Synergy Against Cancer Through Polyamine Metabolism Impairment: Insight Into the Metabolic Effect of Indomethacin on Lung Cancer Cells |
| Q36594374 | Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice |
| Q36958356 | Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice |
| Q24240215 | Single dose oral sulindac for acute postoperative pain in adults |
| Q51068347 | Spermidine Prolongs Lifespan and Prevents Liver Fibrosis and Hepatocellular Carcinoma by Activating MAP1S-Mediated Autophagy. |
| Q30484125 | Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine |
| Q35925417 | Spermine synthase overexpression in vivo does not increase susceptibility to DMBA/TPA skin carcinogenesis or Min-Apc intestinal tumorigenesis |
| Q35002464 | Studies on the metabolism and biological activity of the epimers of sulindac |
| Q37497981 | Sulindac activates NF-κB signaling in colon cancer cells |
| Q37437230 | Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations |
| Q28475579 | Sulindac enhances the killing of cancer cells exposed to oxidative stress |
| Q35065261 | Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs |
| Q35808511 | Supplementation by vitamin D compounds does not affect colonic tumor development in vitamin D sufficient murine models |
| Q39846889 | Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. |
| Q54671666 | Systemic overexpression of antizyme 1 in mouse reduces ornithine decarboxylase activity without major changes in tissue polyamine homeostasis. |
| Q36309384 | TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma |
| Q34164842 | Target delivery and controlled release of the chemopreventive drug sulindac by using an advanced layered double hydroxide nanomatrix formulation system. |
| Q36636354 | Targeted expression of ornithine decarboxylase antizyme prevents upper aerodigestive tract carcinogenesis in p53-deficient mice |
| Q54962055 | Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. |
| Q34080312 | Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans |
| Q38474358 | Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma |
| Q38966691 | Targeting polyamine metabolism for cancer therapy and prevention |
| Q36653461 | Targeting polyamines and inflammation for cancer prevention |
| Q48540832 | The American College of Gastroenterology Emily Couric Lecture--the adenoma-carcinoma sequence revisited: has the era of genetic tailoring finally arrived? |
| Q37084394 | The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBPβ rather than Enterotoxigenic Bacteroides fragilis Infection |
| Q36682108 | The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets |
| Q38643625 | The challenges for cancer chemoprevention |
| Q36983145 | The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome |
| Q35006065 | The cinnamon-derived dietary factor cinnamic aldehyde activates the Nrf2-dependent antioxidant response in human epithelial colon cells |
| Q28087427 | The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism |
| Q35505118 | The mechanisms by which polyamines accelerate tumor spread |
| Q36147300 | The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine |
| Q33761692 | The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification |
| Q38132159 | The proapoptotic effect of traditional and novel nonsteroidal anti-inflammatory drugs in mammalian and yeast cells |
| Q89937434 | The road ahead for health and lifespan interventions |
| Q41817220 | Therapeutic prevention of colorectal carcinogenesis |
| Q36036531 | Time-serial Assessment of Drug Combination Interventions in a Mouse Model of Colorectal Carcinogenesis Using Optical Coherence Tomography |
| Q40830057 | Toxicogenomic Effects in Rat Blood Leukocytes and Chemoprophylaxis of Radiation-Induced Carcinogenesis |
| Q89976996 | Transcriptional and Metabolomic Analysis of L-Arginine/Nitric Oxide Pathway in Inflammatory Bowel Disease and Its Association with Local Inflammatory and Angiogenic Response: Preliminary Findings |
| Q26770306 | Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma |
| Q33636771 | Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. |
| Q33823652 | Tumor inhibition by sodium selenite is associated with activation of c-Jun NH2-terminal kinase 1 and suppression of beta-catenin signaling |
| Q37164803 | Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine |
| Q26765196 | Understanding the molecular mechanisms of cancer prevention by dietary phytochemicals: From experimental models to clinical trials |
| Q88549062 | Updates on Translational Research on Prevention of Polyps and Colorectal Cancer |
| Q37113520 | Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial |
| Q35597150 | Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention |
| Q91905190 | α-Difluoromethylornithine reduces gastric carcinogenesis by causing mutations in Helicobacter pylori cagY |
Search more.